Commercial landscape of noninvasive prenatal testing in the United States.

Autor: Agarwal A; School of Medicine, Duke University, Durham, NC, USA., Sayres LC, Cho MK, Cook-Deegan R, Chandrasekharan S
Jazyk: angličtina
Zdroj: Prenatal diagnosis [Prenat Diagn] 2013 Jun; Vol. 33 (6), pp. 521-31.
DOI: 10.1002/pd.4101
Abstrakt: Cell-free fetal DNA-based noninvasive prenatal testing (NIPT) could significantly change the paradigm of prenatal testing and screening. Intellectual property (IP) and commercialization promise to be important components of the emerging debate about clinical implementation of these technologies. We have assembled information about types of testing, prices, turnaround times, and reimbursement of recently launched commercial tests in the United States from the trade press, news articles, and scientific, legal, and business publications. We also describe the patenting and licensing landscape of technologies underlying these tests and ongoing patent litigation in the United States. Finally, we discuss how IP issues may affect clinical translation of NIPT and their potential implications for stakeholders. Fetal medicine professionals (clinicians and researchers), genetic counselors, insurers, regulators, test developers, and patients may be able to use this information to make informed decisions about clinical implementation of current and emerging noninvasive prenatal tests.
(© 2013 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: